Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cancer02:18

Cancer

54.2K
Cancers arise due to mutations in genes involved in the regulation of cell division, which leads to unrestricted cell proliferation. Modern science and medicine have made great strides in the understanding and treatment of cancer, including eradicating cancer in some patients. However, there is still no cure for cancer. This is largely due to the fact that cancer is a large group of many diseases.
54.2K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

8.9K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.9K
Tumor Immunotherapy01:27

Tumor Immunotherapy

1.9K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
1.9K
What is Cancer?02:12

What is Cancer?

14.4K
Cells and tissues must meticulously coordinate their activities for the normal functioning of the human body. Therefore, they exhibit socially responsible behavior - resting, growing, dividing, differentiating, or dying - for the organism’s benefit. Cancer arises when cells divide uncontrollably and invade other tissues or organs.
Although people have known about cancer for centuries, it was only in 1761 that Giovanni Morgagni of Padua performed a detailed autopsy of...
14.4K
Targets for Drug Action: Overview01:26

Targets for Drug Action: Overview

10.2K
Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
10.2K
Cancer Vaccines01:30

Cancer Vaccines

1.0K
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
1.0K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Anti-Pim-1 mAb inhibits activation and proliferation of T lymphocytes and prolongs mouse skin allograft survival.

Cellular immunology·2011
Same author

Pim-1 expression and monoclonal antibody targeting in human leukemia cell lines.

Experimental hematology·2009
Same author

PIM-1-specific mAb suppresses human and mouse tumor growth by decreasing PIM-1 levels, reducing Akt phosphorylation, and activating apoptosis.

The Journal of clinical investigation·2009
Same author

MUC1 cytoplasmic tail: a potential therapeutic target for ovarian carcinoma.

Expert review of anticancer therapy·2006
Same author

The molecular basis for galalpha(1,3)gal expression in animals with a deletion of the alpha1,3galactosyltransferase gene.

Journal of immunology (Baltimore, Md. : 1950)·2006
Same author

MDX-060. Medarex.

Current opinion in investigational drugs (London, England : 2000)·2005
Same journal

The biological role of CCR4 and its ligands CCL17 and CCL22 in atopic dermatitis: therapeutic implications and future directions.

Expert opinion on therapeutic targets·2026
Same journal

Hepatocyte nuclear factor 4α - prospects for therapeutic targeting.

Expert opinion on therapeutic targets·2026
Same journal

The role of bile acid receptors in cholestatic liver disease: pathophysiological insights and therapeutic advances.

Expert opinion on therapeutic targets·2026
Same journal

Molecular insights for targeting the Nrf1 pathway in hepatocellular carcinoma.

Expert opinion on therapeutic targets·2026
Same journal

Transient receptor potential (TRP) channels: an emerging therapeutic target for the treatment of cardiac hypertrophy.

Expert opinion on therapeutic targets·2026
Same journal

The AT<sub>2</sub> receptor as a potential target for autosomal dominant polycystic kidney disease therapy?

Expert opinion on therapeutic targets·2026
See all related articles

Related Experiment Video

Updated: Jan 31, 2026

Detection of Targetable Alterations in Non-small Cell Lung Cancer using Next-generation Sequencing
05:17

Detection of Targetable Alterations in Non-small Cell Lung Cancer using Next-generation Sequencing

Published on: October 10, 2025

411

Cripto as a target for cancer immunotherapy.

Xiu Feng Hu1, Pei Xiang Xing

  • 1Austin Research Institute, Kronheimer Building, Studley Road, Heidelberg, Victoria, 3084, Australia.

Expert Opinion on Therapeutic Targets
|June 7, 2005
PubMed
Summary
This summary is machine-generated.

The protein Cripto, a key player in embryonic development, promotes cancer growth and spread by driving epithelial-mesenchymal transition (EMT). Targeting its EGF-like region offers a novel therapeutic strategy for cancer immunotherapy.

More Related Videos

Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy
06:51

Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy

Published on: December 17, 2019

16.0K
Preparation of Tumor Antigen-loaded Mature Dendritic Cells for Immunotherapy
08:40

Preparation of Tumor Antigen-loaded Mature Dendritic Cells for Immunotherapy

Published on: August 1, 2013

18.7K

Related Experiment Videos

Last Updated: Jan 31, 2026

Detection of Targetable Alterations in Non-small Cell Lung Cancer using Next-generation Sequencing
05:17

Detection of Targetable Alterations in Non-small Cell Lung Cancer using Next-generation Sequencing

Published on: October 10, 2025

411
Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy
06:51

Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy

Published on: December 17, 2019

16.0K
Preparation of Tumor Antigen-loaded Mature Dendritic Cells for Immunotherapy
08:40

Preparation of Tumor Antigen-loaded Mature Dendritic Cells for Immunotherapy

Published on: August 1, 2013

18.7K

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Research

Background:

  • Cancer immunotherapy advances include targeting molecules regulating cell proliferation and survival.
  • Tumor invasion and metastasis, major causes of cancer mortality, are linked to epithelial-mesenchymal transition (EMT).

Purpose of the Study:

  • This review examines the role of human Cripto in tumorigenesis and EMT.
  • It highlights Cripto's potential as a therapeutic target in cancer immunotherapy.

Main Methods:

  • Review of existing literature on Cripto function in cancer.
  • Analysis of Cripto's role in signaling pathways and EMT.

Main Results:

  • Cripto, an EGF-CFC protein, is upregulated in epithelial cancers and linked to tumor invasion.
  • Cripto's unique EGF-like region is critical for mediating tumor growth and EMT.

Conclusions:

  • Cripto expression drives tumor growth and metastasis through EMT.
  • Targeting the EGF-like region of Cripto presents a promising therapeutic strategy for cancer immunotherapy.